Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIPEP-PAH
- Development stage
- Preclinical
- Lead developer
- Nano Intelligent Biomedical Engineering
- Modality
- Peptides
01
Overview
NIPEP-PAH is a peptide-based therapeutic candidate being developed by Nano Intelligent Biomedical Engineering Corporation (NIBEC) for the treatment of pulmonary arterial hypertension (PAH). The drug is part of NIBEC's proprietary NIPEP (Nano-Intelligent Peptide) platform, which focuses on the development of engineered peptides for regenerative and targeted therapies. NIPEP-PAH is designed to address the underlying vascular remodeling and high blood pressure in the pulmonary arteries associated with PAH. As of early 2024, the program is in the preclinical stage of development, and its specific molecular target has not been publicly disclosed by the developer.
- Other names
- Pulmonary Arterial Hypertension Treatment
Beyond the preview
Go deeper on NIPEP-PAH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIPEP-PAH.